Diversified Trust Co Purchases 1,074 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Diversified Trust Co increased its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 139.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,842 shares of the biotechnology company's stock after buying an additional 1,074 shares during the period. Diversified Trust Co's holdings in United Therapeutics were worth $568,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. raised its position in United Therapeutics by 17.9% during the first quarter. Robeco Institutional Asset Management B.V. now owns 226,287 shares of the biotechnology company's stock valued at $69,757,000 after purchasing an additional 34,362 shares in the last quarter. Illumine Investment Management LLC raised its position in United Therapeutics by 0.7% during the first quarter. Illumine Investment Management LLC now owns 8,604 shares of the biotechnology company's stock valued at $2,652,000 after purchasing an additional 58 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its position in United Therapeutics by 31.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 9,179 shares of the biotechnology company's stock valued at $2,830,000 after purchasing an additional 2,211 shares in the last quarter. State of Alaska Department of Revenue raised its position in United Therapeutics by 0.8% during the first quarter. State of Alaska Department of Revenue now owns 16,692 shares of the biotechnology company's stock valued at $5,145,000 after purchasing an additional 135 shares in the last quarter. Finally, CWA Asset Management Group LLC grew its stake in shares of United Therapeutics by 51.6% during the first quarter. CWA Asset Management Group LLC now owns 8,224 shares of the biotechnology company's stock worth $2,535,000 after buying an additional 2,799 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Up 1.5%

UTHR traded up $4.31 during trading on Wednesday, reaching $295.22. 401,875 shares of the stock traded hands, compared to its average volume of 445,689. The stock has a market capitalization of $13.32 billion, a PE ratio of 11.78, a P/E/G ratio of 6.37 and a beta of 0.53. The stock's 50-day moving average is $301.15 and its 200 day moving average is $323.85. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.17 earnings per share. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on UTHR shares. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. UBS Group lowered their price target on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a report on Monday. HC Wainwright restated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Morgan Stanley increased their price objective on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a report on Thursday, May 1st. Finally, Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and an average price target of $386.15.

Insider Transactions at United Therapeutics

In related news, Director Raymond Dwek sold 4,000 shares of the firm's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the transaction, the director owned 1,750 shares of the company's stock, valued at approximately $497,962.50. This trade represents a 69.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Giltner sold 3,036 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the sale, the director directly owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 91,681 shares of company stock worth $27,319,919 in the last three months. Insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.